ENvue Medical's UroShield® Kit Secures NHS Drug Tariff Inclusion for Nationwide Reimbursement
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 18 2025
0mins
Should l Buy FEED?
Source: Globenewswire
- Reimbursement Milestone: ENvue Medical's UroShield® Kit has been included in the UK NHS Drug Tariff Part IX, establishing a nationwide prescription reimbursement pathway that significantly enhances market access and product availability.
- Initial Order Confirmation: The company has secured an initial purchase order from Peak Medical, a leading UK distributor, reflecting early commercial demand following NHS Drug Tariff inclusion, which is expected to provide early revenue visibility heading into 2026.
- Market Demand Context: Approximately 6-7% of long-term care patients in the UK use urinary catheters, facing a high risk of catheter-associated urinary tract infections; UroShield® aims to reduce these infections through low-frequency ultrasonic energy, thereby improving patient outcomes.
- Strategic Expansion Plans: ENvue Medical's CEO noted that this reimbursement breakthrough removes a major financial barrier, enabling the company to establish a presence in European markets and plans to assess reimbursement frameworks in other countries to support future expansion.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy FEED?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on FEED
About FEED
ENvue Medical, Inc. is a medical technology company advancing both non-invasive and minimally invasive solutions across clinical and home care settings. Its segments include NanoVibronix, ENvue and Corporate. NanoVibronix is engaged in selling its products directly to patients as well as through distributor agreements. ENvue is engaged in selling its systems and Nasoenteral tubes and related services. The Company focuses on two distinct technology platforms: Acoustic-based therapeutic technologies, including PainShield and UroShield, which utilize proprietary low-intensity surface acoustic wave (SAW) technology. These devices are intended for use in home or care settings and are designed to treat pain, reduce bacterial colonization, and disrupt biofilms. The ENvue Navigation Platform, which is a minimally invasive electromagnetic navigation system intended to assist clinicians in placing feeding tubes into the gastrointestinal tract.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Meta Platforms Reports Strong Q4 Earnings, Shares Surge
- Strong Financial Results: Meta reported fourth-quarter revenue of $59.89 billion, exceeding analyst expectations of $58.30 billion, indicating robust performance in the recovering advertising market, which is likely to drive further stock price increases.
- Earnings Growth: The company posted adjusted earnings of $8.88 per share, surpassing the forecast of $8.16 per share, reflecting significant improvements in cost control and operational efficiency, thereby boosting investor confidence.
- Stock Price Surge: Following the earnings report, Meta's shares jumped 8.2% in pre-market trading to $723.70, indicating a positive market sentiment towards the company's growth prospects, which may attract more investor interest.
- Optimistic Sales Guidance: Meta's first-quarter sales guidance exceeded market expectations, further solidifying its leadership position in the digital advertising space and suggesting continued benefits from the recovery in advertising spending.
See More
ENvue Partners with U-Deliver for Nationwide Syringe Distribution
- Stock Surge: ENvue Medical, Inc. (FEED) shares soared 138% on Wednesday following the announcement of a distribution agreement with U-Deliver, indicating strong market enthusiasm for its new product line.
- Product Launch: The recently launched ENFit syringe line is designed to meet clinical needs for both feeding and medication delivery without requiring a prescription, enhancing its competitive edge in the market.
- Distribution Channel Expansion: The new agreement will leverage U-Deliver's digital and wholesale channels to broaden access to the ENFit syringes, which is expected to significantly increase market penetration.
- Market Sentiment Shift: On Stocktwits, retail sentiment around FEED shifted from 'bearish' to 'extremely bullish', with message volume rising from 'low' to 'extremely high', reflecting investor optimism about the company's future prospects.
See More
ENvue Medical Partners with U-Deliver to Expand ENFit Syringe Distribution
- Market Expansion Partnership: ENvue Medical has signed a new distribution agreement with U-Deliver, leveraging its digital and wholesale channels to broaden access to ENFit syringes nationwide, thereby enhancing the company's competitive position in the non-acute enteral care market.
- Product Innovation: The ENFit syringes meet ISO 80369-3 global standards and are available in 2.5 mL, 5 mL, 10 mL, and 60 mL sizes, supporting safe feeding and medication delivery for patients and caregivers.
- Reusable Advantage: These syringes can be reused for up to seven days or 20 uses without a prescription, aimed at supporting continuity of care in home and long-term care settings, thereby improving patient quality of life.
- Stock Performance: Following a 1-for-10 reverse stock split on December 8, 2025, ENvue Medical's stock is currently trading at $2.47, reflecting a 135.67% increase, indicating positive market sentiment towards the new partnership.
See More
ENvue Medical Partners with U-Deliver for Nationwide Distribution of ENFit Syringes
- Distribution Agreement: ENvue Medical has signed a distribution agreement with U-Deliver to distribute its newly launched ENFit syringe product line nationwide through non-acute care channels, aiming to enhance market coverage and meet clinical needs.
- Product Features: The ENFit syringes are designed for reuse, catering to both feeding and medication delivery clinical needs, supporting safe and reliable use in clinical and home care environments with a lifespan of up to seven days or 20 uses.
- Market Performance: ENvue Medical shares rose 20.124% to $1.26 during premarket trading on Wednesday, reflecting positive market response to its new product line, despite the current stock price being close to the 52-week low of $0.99.
- Strategic Rebranding: The company has rebranded to ENvue Medical, which better reflects its new strategic focus on intelligent, non-invasive solutions for enteral care, aiming to strengthen its competitive position in the non-acute enteral care market.
See More
F5, Inc. Reports Strong Q1 Results and Raises FY26 Guidance
- Earnings Beat: F5, Inc. reported Q1 earnings of $4.45 per share, exceeding analyst expectations of $3.65 by 21.88%, indicating a significant improvement in profitability that is likely to positively impact stock prices.
- Revenue Growth: The quarterly revenue reached $822.47 million, surpassing the Street estimate of $758.08 million, demonstrating enhanced competitiveness in the market that may attract more investor interest.
- Optimistic Outlook: The company provided second-quarter sales guidance above estimates and raised its FY26 guidance, reflecting management's confidence in future growth, which could further drive stock price increases.
- Positive Stock Reaction: F5 shares jumped 10.9% to $299.99 in pre-market trading, indicating strong market response to its earnings report, which may draw in more investors and bolster market confidence.
See More
ENvue Medical Appoints Marc Waldman as VP of Commercial to Drive Revenue Growth
- Leadership Change: ENvue Medical has appointed Marc Waldman as Vice President of Commercial, where he will lead the company's U.S. commercialization strategy across 38 hospitals, aiming to accelerate revenue growth and expand market presence.
- Extensive Industry Experience: Waldman brings over 35 years of experience in the medical device industry, having previously worked at NeoMed and Avanos Medical, where he successfully increased North American sales from approximately $39 million to $70 million, showcasing his exceptional sales leadership.
- Strategic Execution: During his tenure at Avanos, Waldman guided the organization through a significant transition from a dealer-only model to a hybrid structure, leveraging both direct and dealer partnerships to enhance market competitiveness and optimize the business model.
- Industry Influence: As Chairperson of the Global Enteral Device Supplier Association, Waldman plays a crucial role in advancing enteral safety standards, further enhancing ENvue's influence and reputation within the healthcare industry.
See More
Meta Platforms Reports Strong Q4 Earnings, Shares Surge
- Strong Financial Results: Meta reported fourth-quarter revenue of $59.89 billion, exceeding analyst expectations of $58.30 billion, indicating robust performance in the recovering advertising market, which is likely to drive further stock price increases.
- Earnings Growth: The company posted adjusted earnings of $8.88 per share, surpassing the forecast of $8.16 per share, reflecting significant improvements in cost control and operational efficiency, thereby boosting investor confidence.
- Stock Price Surge: Following the earnings report, Meta's shares jumped 8.2% in pre-market trading to $723.70, indicating a positive market sentiment towards the company's growth prospects, which may attract more investor interest.
- Optimistic Sales Guidance: Meta's first-quarter sales guidance exceeded market expectations, further solidifying its leadership position in the digital advertising space and suggesting continued benefits from the recovery in advertising spending.
See More
ENvue Partners with U-Deliver for Nationwide Syringe Distribution
- Stock Surge: ENvue Medical, Inc. (FEED) shares soared 138% on Wednesday following the announcement of a distribution agreement with U-Deliver, indicating strong market enthusiasm for its new product line.
- Product Launch: The recently launched ENFit syringe line is designed to meet clinical needs for both feeding and medication delivery without requiring a prescription, enhancing its competitive edge in the market.
- Distribution Channel Expansion: The new agreement will leverage U-Deliver's digital and wholesale channels to broaden access to the ENFit syringes, which is expected to significantly increase market penetration.
- Market Sentiment Shift: On Stocktwits, retail sentiment around FEED shifted from 'bearish' to 'extremely bullish', with message volume rising from 'low' to 'extremely high', reflecting investor optimism about the company's future prospects.
See More
ENvue Medical Partners with U-Deliver to Expand ENFit Syringe Distribution
- Market Expansion Partnership: ENvue Medical has signed a new distribution agreement with U-Deliver, leveraging its digital and wholesale channels to broaden access to ENFit syringes nationwide, thereby enhancing the company's competitive position in the non-acute enteral care market.
- Product Innovation: The ENFit syringes meet ISO 80369-3 global standards and are available in 2.5 mL, 5 mL, 10 mL, and 60 mL sizes, supporting safe feeding and medication delivery for patients and caregivers.
- Reusable Advantage: These syringes can be reused for up to seven days or 20 uses without a prescription, aimed at supporting continuity of care in home and long-term care settings, thereby improving patient quality of life.
- Stock Performance: Following a 1-for-10 reverse stock split on December 8, 2025, ENvue Medical's stock is currently trading at $2.47, reflecting a 135.67% increase, indicating positive market sentiment towards the new partnership.
See More
ENvue Medical Partners with U-Deliver for Nationwide Distribution of ENFit Syringes
- Distribution Agreement: ENvue Medical has signed a distribution agreement with U-Deliver to distribute its newly launched ENFit syringe product line nationwide through non-acute care channels, aiming to enhance market coverage and meet clinical needs.
- Product Features: The ENFit syringes are designed for reuse, catering to both feeding and medication delivery clinical needs, supporting safe and reliable use in clinical and home care environments with a lifespan of up to seven days or 20 uses.
- Market Performance: ENvue Medical shares rose 20.124% to $1.26 during premarket trading on Wednesday, reflecting positive market response to its new product line, despite the current stock price being close to the 52-week low of $0.99.
- Strategic Rebranding: The company has rebranded to ENvue Medical, which better reflects its new strategic focus on intelligent, non-invasive solutions for enteral care, aiming to strengthen its competitive position in the non-acute enteral care market.
See More
F5, Inc. Reports Strong Q1 Results and Raises FY26 Guidance
- Earnings Beat: F5, Inc. reported Q1 earnings of $4.45 per share, exceeding analyst expectations of $3.65 by 21.88%, indicating a significant improvement in profitability that is likely to positively impact stock prices.
- Revenue Growth: The quarterly revenue reached $822.47 million, surpassing the Street estimate of $758.08 million, demonstrating enhanced competitiveness in the market that may attract more investor interest.
- Optimistic Outlook: The company provided second-quarter sales guidance above estimates and raised its FY26 guidance, reflecting management's confidence in future growth, which could further drive stock price increases.
- Positive Stock Reaction: F5 shares jumped 10.9% to $299.99 in pre-market trading, indicating strong market response to its earnings report, which may draw in more investors and bolster market confidence.
See More
ENvue Medical Appoints Marc Waldman as VP of Commercial to Drive Revenue Growth
- Leadership Change: ENvue Medical has appointed Marc Waldman as Vice President of Commercial, where he will lead the company's U.S. commercialization strategy across 38 hospitals, aiming to accelerate revenue growth and expand market presence.
- Extensive Industry Experience: Waldman brings over 35 years of experience in the medical device industry, having previously worked at NeoMed and Avanos Medical, where he successfully increased North American sales from approximately $39 million to $70 million, showcasing his exceptional sales leadership.
- Strategic Execution: During his tenure at Avanos, Waldman guided the organization through a significant transition from a dealer-only model to a hybrid structure, leveraging both direct and dealer partnerships to enhance market competitiveness and optimize the business model.
- Industry Influence: As Chairperson of the Global Enteral Device Supplier Association, Waldman plays a crucial role in advancing enteral safety standards, further enhancing ENvue's influence and reputation within the healthcare industry.
See More
